FMP
NASDAQ
18.14 USD
0.015 (0.08269%)
Dr. Jean-Paul Kress M.D.
Healthcare
Biotechnology
https://www.morphosys.com
NASDAQ
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a ...
0001340243
US6177602025
617760202
Semmelweisstrasse 7
49 89 89927 0
DE
524
Apr 19, 2018
0001340243
NASDAQ
Biotechnology
Healthcare
617760202
US6177602025
DE
18.14
0.61
2.13M
2.73B
-
3.89-18.305
4.93
-
-
-
-
-12.09
-
https://www.morphosys.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.